1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Non-Invasive Cancer Diagnostics Market, 2015-2030

Non-Invasive Cancer Diagnostics Market, 2015-2030

  • October 2015
  • -
  • Roots Analysis Private Ltd.
  • -
  • 229 pages

INTRODUCTION
Cancer is an extremely complex disease and medical science is still struggling to figure out the factors influencing the disease origin, propagation, spread (metastasis) and relapse. In addition to satisfying the unmet market need for advanced and efficient treatment interventions, cancer prevention, early detection and management is extremely important. The high cancer mortality rate is primarily due to delay in detection of the disease. Early diagnosis and screening makes it possible to cure the disease completely and/or increase survival rates. Over the years, various technological advances have helped medical professionals understand cancer better. Recent research in cancer biology has led to a lot of innovation in the development of a number of new diagnostic tools. These modern diagnostic techniques can help detect and classify cancer with increased accuracy and sensitivity.

It is also important to highlight that the cost of management and treatment of cancer is a growing concern considering its highly progressive and fatal nature. Performing a biopsy includes costs associated with the equipment, cost of the procedure itself, consultation fees, hospital fees, costs of analytical tests and those associated with post-operative care. To manage this financial burden, the introduction of novel non-invasive techniques, which are cost-effective and more accurate, has become an indispensable necessity.

There are several advanced approaches, which are non-invasive or minimally invasive in nature, and these outweigh the limitations posed by invasive diagnostic procedures. Specifically, liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool for early detection as well as monitoring the disease’s progress. This technique of tracing the presence of circulating biomarkers in blood and other biological fluids of cancer patients is becoming increasingly popular in the medical fraternity. In addition to liquid biopsy, the market is gradually witnessing the emergence of several other non-invasive diagnostic technologies. These include techniques based on molecular imaging, advanced genomic and transcriptomic methods of detection of clinically significant biomarkers and identification of nucleosomal levels. All such non-invasive tests hold a significant promise to enhance the quality of patient care.

SCOPE OF THE REPORT
The ‘Non-Invasive Cancer Diagnostics Market, 2015-2030’ report provides an extensive study on liquid biopsy kits/assays that are either commercialised or under development for the diagnosis of different types of cancer. Liquid biopsy primarily focuses on the detection, isolation and characterisation of biomarkers from circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) or exosomes present in biological fluids, which can be collected in a single blood draw. The market is characterised by the presence of several companies that have proprietary technologies/platforms for either isolation/enrichment/enumeration of CTCs or molecular characterisation/sequencing of the genetic material extracted from the CTCs/exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, patient and recurrence monitoring. It is important to stress that even though liquid biopsy has still not made a strong foothold in the field of oncology, it is likely to transform the cancer diagnostics market with many commercial success stories in the near future.

In addition to liquid biopsy, there are several other novel and promising non-invasive diagnostics being developed for the diagnosis and prognosis of cancer. However, these tests are only indicative of the disease and may require further validation through more robust diagnostic methods such as biopsy. These tests retrieve the test sample non-invasively and use innovative techniques to screen for the desired parameters indicative of the disease with a moderate level of accuracy. Some of these are designed to be used at home by the patient itself.

As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analysing:
- The global burden of cancer in terms of incidence and prevalence of different cancer indications across different geographies.
- The overall landscape of liquid biopsies and other novel diagnostic tests with respect to the type of analysis (CTCs/ctNA/exosomes), test sample source (blood/urine/others) and indications.
- The likely global evolution of the liquid biopsy market taking into account initial diagnosis, recurrence monitoring and patient monitoring.
- Contribution of other novel diagnostic tests in the non-invasive cancer diagnostics market and the market opportunity of the key indications influencing the overall growth.

We have provided three market forecast scenarios for the time period 2015-2030. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. Our opinions and insights, presented in this study, were influenced by discussions that we conducted with experts in this area. All actual figures have been sourced and analysed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 presents an executive summary of the report. It offers a high level view on where the market for liquid biopsy and other novel non-invasive diagnostics is headed in the mid to long term.

Chapter 3 provides a general introduction to cancer statistics and burden of the disease worldwide. In this section, we have also highlighted the importance of early detection of the disease through diagnosis and asymptomatic screening. The chapter outlines the conventional invasive diagnostic tests, which are widely used for cancer diagnosis and prognosis.

Chapter 4 discusses in detail the need for non-invasive cancer diagnostics and their importance. We have highlighted the underlying concept of liquid biopsy and other non-invasive tests. In addition, we have mentioned the principle behind common imaging tests that are deployed in cancer diagnosis.

Chapter 5 provides a holistic view of the non-invasive cancer diagnostics landscape. It enlists the liquid biopsy tests, technologies and systems. In addition, it offers a list of other non-invasive tests. These lists include information on the developer, technology used by the product, test sample source and indication. We have also mapped the geographical presence of the enlisted non-invasive cancer diagnostics developers.

Chapter 6 offers a comprehensive discussion on liquid biopsy. We have talked about the emerging need for liquid biopsy highlighting its advantages and challenges. In addition, we have provided technology profiles and product profiles of several liquid biopsy products. The chapter also mentions the liquid biopsy companion diagnostics, which are being co-developed as part of strategic collaborations.

Chapter 7 provides an overview of the other novel non-invasive diagnostics used in oncology. It highlights the different imaging based diagnostic procedures, biomarker and nucleosome based diagnostics, skin lesion and breath based diagnostics. The diagnostic procedures discussed in this chapter are backed up by several examples.

Chapter 8 highlights the market forecast and sizing of the overall non-invasive cancer diagnostics market. This chapter discusses, in detail, the parameters likely to influence the evolution of liquid biopsy market. In addition, we have also presented the market share of other non-invasive diagnostic tests and an opportunity analysis for the key indications likely to have the maximum impact on the overall market.

Chapter 9 provides detailed company profiles of the leading players in the market involved in the development of liquid biopsy as well as other non-invasive tests. Amongst other details, each profile includes information such as the company overview, financial performance, product portfolio and recent collaborations.

Chapter 10 summarises the overall report. In this chapter, we list the key takeaways and provide our independent opinion based on the research and analysis described in previous chapters.

Chapter 11 is a collection of interview transcripts of the discussions that were held during the course of this study.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix, which provides the list of companies and organisations mentioned in the report.

EXAMPLE HIGHLIGHTS
1. We have identified over 50 liquid biopsy tests; some of these are commercialised and the rest are currently under development. Of these, 50% tests are based on the identification of disease biomarkers in ctDNA of the test sample. Nearly 37% of the tests are based on the enumeration/analysis of CTCs in the sample and the remaining 13% validate the presence of the disease from the information obtained from exosomes.
2. Several companies are developing systems and instruments to support the detection, isolation and characterisation of rare cells. Examples include (in no specific order) the Parsortix System by ANGLE, ScreenCell® Isolation Devices by ScreenCell, ApoStream™ System by ApoCell, ClearCell FX® System by Clearbridge BioMedics and iCellate® Instrument by iCellate Medical.
3. Firms have also taken initiatives and entered into collaborations to co-develop liquid biopsy companion diagnostic products; notable examples include collaborations between Tokai Pharmaceuticals and Qiagen, AstraZeneca and Qiagen, Sysmex Inostics and Bayer HealthCare.
4. In addition to liquid biopsy, we have identified close to 40 other non-invasive cancer diagnostics that are used for screening, diagnosis, prognosis and patient monitoring; these include techniques based on molecular imaging, advanced methods of detecting clinically significant biomarkers and identification of nucleosomal levels.
5. Primarily driven by liquid biopsy, the non-invasive cancer diagnostics market is anticipated to grow aggressively at a healthy annual growth rate of 44% between 2015 and 2030. Prostate cancer, breast cancer, colorectal cancer and lung cancer are likely to be the key indications which will drive the market; combined, these are expected to account for over 70% of the total liquid biopsy market in 2030.

Table Of Contents

Non-Invasive Cancer Diagnostics Market, 2015-2030
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease
3.3. Importance of Early Detection in Cancer
3.4. Detecting Cancer: Screening versus Diagnosis
3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Approaches

4. CONCEPT OF NON-INVASIVE CANCER SCREENING AND DIAGNOSTICS
4.1. Chapter Overview

4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerised Tomography (CT) Scan
4.2.5. Integrated PET-CT Scan
4.2.6. Ultrasound
4.2.7. Barium Enema

4.3. Screening Assays
4.3.1. Pap Test and HPV Test
4.3.2. Tumour Marker Tests
4.3.3. Faecal Occult Blood Tests (FOBT)
4.3.4. Digital Rectal Exam (DRE)
4.3.5. MUGA Scan

4.4. Advanced Non-Invasive Approaches
4.4.1. Liquid Biopsy
4.4.2. Cytogenetic/Gene Expression Studies
4.4.3. Molecular Signature Based Non-Invasive Methods
4.4.4. Saliva-Based Oral Cancer Diagnostics
4.4.5. Vital Staining
4.4.6. Optical Biopsy
4.4.7. Other Techniques

5. MARKET OVERVIEW
5.1. Chapter Overview

5.2. Liquid Biopsy: Market Landscape
5.2.1. Liquid Biopsy: Distribution by Type of Analysis
5.2.2. Liquid Biopsy: Distribution by Sample Source
5.2.3. Liquid Biopsy: Distribution by Indication
5.2.4. Liquid Biopsy: Distribution by Region
5.3. Liquid Biopsy Technologies and Systems/Instruments

5.4. Other Non-Invasive Cancer Diagnostic Tests: Market Landscape
5.4.1. Other Non-Invasive Tests: Distribution by Sample Source
5.4.2. Other Non-Invasive Tests: Distribution by Indication
5.4.3. Other Non-Invasive Tests: Distribution by Region

6. LIQUID BIOPSY: DETAILED OUTLOOK
6.1. Chapter Overview
6.2. Non-Invasive Detection of Cancer over Biopsies
6.3. Circulating Biomarkers for Cancer
6.3.1. CTCs and ctcDNA
6.3.2. ctDNA
6.3.3. Exosomes

6.4. Liquid Biopsy Based Technology, Systems and Tests
6.4.1. ApoStream® Technology and ApoStream® CTC Test (ApoCell)
6.4.1.1. Overview
6.4.1.2. Results
6.4.1.3. Collaborations
6.4.1.4. Funding

6.4.2. BioFluidica CTC Isolation Technology and CTC Analysis System (BioFluidica/Roche)
6.4.2.1. Overview
6.4.3.2. Results
6.4.3.3. Collaborations

6.4.3. CELLSEARCH® System and CELLSEARCH® CTC Test (Janssen Diagnostics)
6.4.3.1. Overview
6.4.3.2. Results
6.4.3.3. Collaborations
6.4.3.4. Other Developments

6.4.4. LiquidBiopsy® Rare Cell Isolation Platform and ClearID Test (Cynvenio Biosystems)
6.4.4.1. Overview
6.4.4.2. Collaborations
6.4.4.3. Other Developments
6.4.4.4. Funding

6.4.5. Parsortix System (ANGLE)
6.4.5.1. Overview
6.4.5.2. Results
6.4.5.3. Collaborations
6.4.5.4. Funding

6.4.6. QuantiGene® ViewRNA CTC Platform and Assay (Affymetrix)
6.4.6.1. Overview
6.4.6.2. Collaborations

6.4.7. IVDxTx Platform Technology and IVD CTC Assays (IVDiagnostics)
6.4.7.1. Overview
6.4.7.2. Collaborations
6.4.7.3. Other Developments
6.4.7.4. Funding

6.4.8. iCellate® (iCellate AB)
6.4.8.1. Overview
6.4.8.2. Collaborations

6.5. Liquid Biopsy and Companion Diagnostic Products
6.5.1. Tokai Pharmaceuticals and Qiagen
6.5.2. AstraZeneca and Qiagen
6.5.3. Sysmex Inostics and Bayer HealthCare

7. OTHER NOVEL NON-INVASIVE TECHNOLOGIES
7.1. Chapter Overview
7.2. Imaging Based Diagnostics
7.3. Biomarker and Nucleosome Detection
7.4. Skin Lesion Based Diagnosis
7.5. Diagnostic Breath Testing

8. MARKET SIZING AND FORECAST
8.1. Chapter Overview
8.2. Methodology
8.3. Overall Non-Invasive Cancer Diagnostic Market
8.4. Liquid Biopsy Market
8.4.1. Initial Diagnosis
8.4.2. Recurrence Monitoring
8.4.3. Patient Monitoring
8.4.4. Market Forecast Projections, 2015-2030
8.5. Opportunity Analysis for Important Indications
8.5.1. Prostate Cancer
8.5.2. Breast Cancer
8.5.3. Colorectal Cancer
8.5.4. Lung Cancer
8.6. Non-Invasive Cancer Diagnostics Market: Regional Distribution

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Companies with Focus on Liquid Biopsy
9.2.1. Biocept
9.2.1.1. Company Overview
9.2.1.2. Financial Performance
9.2.1.3. Product Portfolio
9.2.1.4. Collaborations

9.2.2. Exosome Diagnostics
9.2.2.1. Company Overview
9.2.2.2. Product Portfolio
9.2.2.3. Collaborations

9.2.4. Genomic Health
9.2.4.1. Company Overview
9.2.4.2. Financial Performance
9.2.4.3. Product Portfolio
9.2.4.4. Collaborations

9.2.5. Guardant Health
9.2.5.1. Company Overview
9.2.5.2. Product Portfolio
9.2.5.3. Collaborations
9.2.6. Qiagen
9.2.6.1. Company Overview
9.2.6.2. Financial Performance
9.2.6.3. Product Portfolio
9.2.6.4. Collaborations

9.2.7. Trovagene
9.2.7.1. Company Overview
9.2.7.2. Financial Performance
9.2.7.3. Product Portfolio
9.2.7.4. Collaborations

9.3. Companies with Focus on Other Non-Invasive Diagnostic Techniques
9.3.1. bioMerieux
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Portfolio
9.3.1.4. Collaborations

9.3.2. Cepheid
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Portfolio
9.3.2.4. Collaborations

9.3.3. DermTech
9.3.3.1. Company Overview
9.3.3.2. Product Portfolio
9.3.3.3. Collaborations

9.3.4. DiagnoCure
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Portfolio
9.3.4.4. Collaborations

9.3.5. Exact Sciences
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Portfolio
9.3.5.4. Collaborations

9.3.7. Pacific Edge
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Portfolio
9.3.7.4. Collaborations

10. CONCLUSION
10.1. Improved Cancer Detection and Patient Care: A Growing Necessity
10.2. Introduction of Sophisticated Molecular Diagnostics: A Solution to the Existing Unmet Need
10.3. Liquid Biopsy: The Potential Replacement to Invasive Techniques
10.4. Other Non-Invasive Tests: Further Enhancing the Cancer Diagnostics Portfolio
10.5 With Liquid Biopsy at the Forefront, Non-Invasive Cancer Diagnostics Expected to Emerge as a Multi-Billion Dollar Market

11. INTERVIEW TRANSCRIPTS
11.1. Christer Ericsson, Chief Scientific Officer, iCellate AB
11.2. Philippe Nore, CEO and Co-founder, MiNDERA Corporation
11.3. Dr. Jake Micallef, Chief Scientific Officer, VolitionRx

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures
Figure 3.1 Worldwide Incidence: Distribution by Type of Cancer
Figure 3.2 Lung Cancer: Estimated New Cases in 2015 (in'000s)
Figure 3.3 Breast Cancer: Estimated New Cases in 2015 (in ‘000s)
Figure 3.4 Colorectal Cancer: Estimated New Cases in 2015 (in ‘000s)
Figure 3.5 Factors Determining Useful Cancer Screening
Figure 3.6 Conventional Cancer Diagnosis Methods
Figure 3.7 Needle Biopsy and Open Biopsy: Demerits
Figure 4.1 Broad Categories of Non-Invasive Cancer Screening and Diagnostics
Figure 4.2 Types of Diagnostic Imaging
Figure 4.3 Types of Screening Assays
Figure 4.4 Types of Advanced Non-Invasive Approaches
Figure 5.1 Liquid Biopsy: Distribution by Type of Analysis
Figure 5.2 Liquid Biopsy: Distribution by Sample Source
Figure 5.3 Liquid Biopsy: Distribution by Indication
Figure 5.4 Liquid Biopsy: Distribution by Region
Figure 5.5 Other Non-Invasive Tests: Distribution by Sample Source
Figure 5.6 Other Non-Invasive Tests: Distribution by Indication
Figure 5.7 Other Non-Invasive Tests: Distribution by Region
Figure 6.1 Circulating Biomarkers for Cancer
Figure 6.2 ApoStream® Technology: Advantages
Figure 6.3 BioFluidica CTC Isolation System Workflow
Figure 6.4 BioFluidica System: Advantages
Figure 6.5 CELLSEARCH® System: Basic Steps
Figure 6.6 CELLSEARCH® System Workflow
Figure 6.7 LiquidBiopsy® Workflow
Figure 6.8 LiquidBiopsy® and Ion Torrent PGM Workflow Components
Figure 6.9 Parsortix System Workflow
Figure 6.10 ViewRNA CTC Platform Workflow
Figure 6.11 iCellate® Workflow
Figure 8.1 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Base Case, 2015-2022
Figure 8.2 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Base Case, 2022-2030
Figure 8.3 Liquid Biopsy Market (USD Million), Short Term, Base Case, 2015-2022
Figure 8.4 Liquid Biopsy Market (USD Million), Mid-Long Term, Base Case, 2022-2030
Figure 8.5 Prostate Cancer Liquid Biopsy Market (USD Million)
Figure 8.6 Breast Cancer Liquid Biopsy Market (USD Million)
Figure 8.7 Colorectal Cancer Liquid Biopsy Market (USD Million)
Figure 8.8 Lung Cancer Liquid Biopsy Market (USD Million)
Figure 8.9 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2022
Figure 8.10 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2030
Figure 9.1 Biocept Revenues, 2012- H1 2015 (USD Million)
Figure 9.2 Genomic Health Revenues, 2010- H1 2015 (USD Million)
Figure 9.3 Qiagen Revenues, 2010-Q1 2015 (USD Billion)
Figure 9.4 Qiagen Revenues, Q1 2015, Distribution by Business Segments (Share in %)
Figure 9.5 Trovagene Revenues, 2010-Q1 2015 (USD Million)
Figure 9.6 bioMerieux Revenues, 2011-Q1 2015 (EUR Billion)
Figure 9.7 bioNexia® FOB versus Guaiac Based Tests: Sensitivity for Positive Results
Figure 9.8 Cepheid Revenues, 2010- H1 2015 (USD Million)
Figure 9.9 Cepheid Revenues: Distribution by Type of Sales, 2014 (USD Million)
Figure 9.10 DiagnoCure Revenues, 2010-H1 2015 (USD Million)
Figure 9.11 Exact Sciences Revenues, 2010-HI 2015 (USD Million)
Figure 9.12 Pacific Edge Revenues, 2010-2014 (USD Million)
Figure 9.13 Cxbladder®: Biomarker Genes
Figure 10.1 Non-Invasive Cancer Diagnostic Market (USD Million), 2015, 2022 and 2030

List of Tables
Table 3.1 Survival on Early Diagnosis of Cancer
Table 3.2 Cost of Biopsy for Different Cancer Indications
Table 3.3 Common Endoscopic Procedures
Table 4.1 Examples of Tumour Markers
Table 5.1 Non-Invasive Cancer Diagnostics: Liquid Biopsy Tests
Table 5.2 Non-Invasive Cancer Diagnostics: Liquid Biopsy Technologies
Table 5.3 Non-Invasive Cancer Diagnostics: Liquid Biopsy Systems/ Instruments
Table 5.4 Non-Invasive Cancer Diagnostics: Other Screening and Diagnostic Tests
Table 6.1 Aspects of Biopsies versus Liquid Biopsies
Table 6.2 Liquid Biopsy Based Diagnostics: Example List
Table 6.3 Comparison between ApoStream CTC Test and CELLSEARCH® CTC Test
Table 6.4 ApoCell: Funding Instances
Table 6.5 Comparison of the Clinical Sensitivity of BioFluidica Technology and CELLSEARCH® Technology
Table 6.6 CELLSEARCH® CTC Test: Cut-offs For Disease Prognosis
Table 6.7 Cynvenio Biosystems: Funding Rounds
Table 6.8 ANGLE: Funding Rounds
Table 6.9 IVD CTC Tests: Potential Indications
Table 6.10 IVDiagnostics: Funding Rounds
Table 7.1 Sensitivity/Specificity: Individual Technologies versus Combination
Table 7.2 Imaging Based Diagnostics: Example List
Table 7.3 Biomarker and Nucleosome Detection Based Diagnostics: Example List
Table 7.4 Skin Lesion Based Diagnostics: Example List
Table 7.5 Diagnostic Breath Testing Devices: Example List
Table 8.1 Liquid Biopsy for Initial Diagnosis: Market Forecast Assumptions
Table 8.2 Liquid Biopsy for Recurrence Monitoring: Market Forecast Assumptions
Table 8.3 Liquid Biopsy for Patient Monitoring: Market Forecast Assumptions
Table 9.1 Q1Aamp® Circulating Nucleic Acid Kit: Specifications
Table 9.2 VIDAS® Tumour Markers: Specifications
Table 9.3 VIDAS® Tumour Markers, 2011-2014
Table 9.4 Xpert® HPV: Comparative Clinical Performance
Table 9.5 ImmunoCytâ„¢/uCYT+â„¢: Comparison with Other Urinary Cancer Biomarker Assays
Table 9.6 PCA3 Test: Launch Years for Respective Geographies
Table 12.1 Worldwide Incidence: Distribution by Type of Cancer
Table 12.2 Lung Cancer: Estimated New Cases in 2015 (in ‘000s)
Table 12.3 Breast Cancer: Estimated New Cases in 2015 (in ‘000s)
Table 12.4 Colorectal Cancer: Estimated New Cases in 2015 (in ‘000s)
Table 12.5 Liquid Biopsy: Distribution by Type of Analysis
Table 12.6 Liquid Biopsy: Distribution by Sample Source
Table 12.7 Liquid Biopsy: Distribution by Indication
Table 12.8 Liquid Biopsy: Distribution by Region
Table 12.9 Other Non-Invasive Diagnostic Tests: Distribution by Sample Source
Table 12.10 Other Non-Invasive Diagnostic Tests: Distribution by Indication
Table 12.11 Other Non-Invasive Diagnostic Tests: Distribution by Region
Table 12.12 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Base Case, 2015-2022
Table 12.13 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Base Case, 2022-2030
Table 12.14 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Optimistic Case, 2015-2022
Table 12.15 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Optimistic Case, 2022-2030
Table 12.16 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Conservative Case, 2015-2022
Table 12.17 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term Conservative Case, 2022-2030
Table 12.18 Liquid Biopsy Market (USD Million), Short Term, Base Case, 2015-2022
Table 12.19 Liquid Biopsy Market (USD Million), Mid-Long Term, Base Case, 2022-2030
Table 12.20 Liquid Biopsy Market (USD Million), Short Term, Optimistic Case, 2015-2022
Table 12.21 Liquid Biopsy Market (USD Million), Mid-Long Term, Optimistic Case, 2022-2030
Table 12.22 Liquid Biopsy Market (USD Million), Short Term, Conservative Case, 2015-2022
Table 12.23 Liquid Biopsy Market (USD Million), Mid Long Term, Conservative Case, 2022-2030
Table 12.24 Prostate Cancer Liquid Biopsy Market (USD Million)
Table 12.25 Breast Cancer Liquid Biopsy Market (USD Million)
Table 12.26 Colorectal Cancer Liquid Biopsy Market (USD Million)
Table 12.27 Lung Cancer Liquid Biopsy Market (USD Million)
Table 12.28 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2022
Table 12.29 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2030
Table 12.30 Biocept Revenues, 2012- H1 2015 (USD Million)
Table 12.31 Genomic Health Revenues, 2010- H1 2015 (USD Million)
Table 12.32 Qiagen Revenues, 2010-Q1 2015 (USD Billion)
Table 12.33 Qiagen Revenues, Q1 2015, Split by Business Segments (Share in %)
Table 12.34 Trovagene Revenues, 2010-Q1 2015 (USD Million)
Table 12.35 bioMerieux Revenues, 2011-Q1 2015 (EUR Billion)
Table 12.36 bioNexia® FOB versus Guaiac Based Tests: Sensitivity for Positive Results
Table 12.37 Cepheid Revenues, 2010- H1 2015 (USD Million)
Table 12.38 Cepheid Revenues: Distribution by Type of Sales, 2014 (USD Million)
Table 12.39 DiagnoCure Revenues, 2010-H1 2015 (USD Million)
Table 12.40 Exact Sciences Revenues, 2010-HI 2015 (USD Million)
Table 12.41 Pacific Edge Revenues, 2010-2014 (USD Million)
Table 12.42 Lung Cancer Liquid Biopsy Market (USD Million), 2015, 2022, 2030
Companies Mentioned
The following companies and organisations have been mentioned in this report.


1. AandG Pharmaceutical
2. Accelerate Brain Cancer Cure
3. Acousys Biodevices
4. Addario Lung Cancer Medical Institute
5. Admera Health
6. AdnaGen
7. Affymetrix
8. Agena Bioscience
9. Almac Group
10. America's Choice Provider Network
11. American Lung Association
12. Angle plc
13. Anixa Diagnostics Corporation
14. ApoCell
15. ARUP Laboratories
16. Astellas Pharma
17. AstraZeneca
18. Astute Medical
19. Aviva Biosciences
20. Barts Cancer Institute
21. Bayer Healthcare
22. BC Cancer Agency
23. BGI Tech Solutions
24. Biocartis
25. Biocept
26. Biodesix
27. BioFluidica
28. bioMerieux
29. Biosense Medical
30. Biotype Diagnostics
31. BioView
32. Boreal Genomics
33. Brigham and Women's Hospital
34. Canopus Bioscience
35. Catholic Health Initiatives Center
36. Clarient
37. Clearbridge BioMedics
38. Clovis Oncology
39. CollabRx
40. Columbia University
41. Comprehensive Cancer Center
42. COPAN
43. Creatv MicroTech
44. Cubist Pharmaceuticals
45. Cynvenio Biosystems
46. CytoTrack
47. CytoLumina Technologies
48. Dana Farber Cancer Institute
49. Datar Generics
50. Denovo Sciences
51. DermTech
52. DiagnoCure
53. Diagnologix
54. Digene Corporation
55. Drug Response Dx
56. EKF Molecular Diagnostics
57. Eli Lilly
58. Epic Sciences
59. Epigenomics
60. European Medical Network for Translational Research in Ovarian Cancer
61. Exact Sciences
62. Exosome Diagnostics
63. Exosomics Siena
64. Fairview Health Services
65. FedMed
66. Flatiron Health
67. Fluxion Biosciences
68. Foundation Medicine
69. Fraunhofer Institute for Cell Therapy and Immunology
70. Genomic Health
71. Genoptix
72. Gensignia
73. GlaxoSmithKline
74. Guangdong Medical College
75. Guardant Health
76. Hain Lifescience
77. HansaBioMed
78. Healthscope Pathology
79. Hitachi High-Technologies
80. iCellate Medical
81. Illumina
82. Incyte Genomics
83. Inivata
84. Insight Genetics
85. Ipsen
86. Ironwood Pharmaceuticals
87. IVDiagnostics
88. Janssen Diagnostics
89. OHSU Knight Cancer Institute
90. Labcorp
91. London Health Sciences Centre
92. Louisiana State University
93. Massachusetts General Hospital
94. Mayo Clinic
95. Mayo Medical Laboratory Network
96. MD Anderson Cancer Center
97. MDx Health
98. Medical University of Vienna
99. MELA Sciences
100. Merck Serono
101. MiNDERA
102. MolecularMD
103. Molecular Pathology Laboratory Network
104. Natera
105. National Cancer Institute
106. NeoGenomics Laboratory
107. Novartis
108. Novigenix
109. Ortho Biotech Oncology Research and Development
110. Pacific Edge
111. Palex Medical
112. Pathway Genomics
113. PathQC
114. Personal Genome Diagnostics
115. Promega Corporation
116. Prostate Cancer Foundation
117. Qiagen
118. Quanterix
119. Quest Diagnostics
120. RainDance Technologies
121. Rarecells Diagnostics
122. RareCyte
123. Roche
124. Rosetta Genomics
125. Roswell Park Cancer Institute
126. Royal Philips Electronics
127. Rutgers New Jersey Medical School
128. SAIC-Frederick
129. Sarah Cannon Research Institute
130. ScheBo
131. ScreenCell
132. Siemens
133. Sequenom
134. Shimadzu
135. Shuwen Biotech
136. Signal Genetics
137. Signature Diagnostics
138. Silicon Biosystems
139. SIMSYS
140. Skyline Diagnostics
141. Southern California Permanente Medical Group
142. SRI International
143. StableBody Technologies
144. Stiefel Laboratories
145. Strand Life Sciences
146. Sysmex Inostics
147. Tan Tock Seng Hospital
148. Targeted Diagnostics and Therapeutics
149. Technion-Israel Institute of Technology
150. The Valld'Hebron Institute of Oncology
151. Thermo Fisher Scientific
152. Thomas Jefferson University
153. Tokai Pharmaceuticals
154. Transgenomic
155. Trovagene
156. Tumour Bank Ovarian Cancer Network
157. University of California
158. University of Dusseldorf
159. University of Michigan
160. University of Nijmegen
161. University of Southern California
162. University of Texas
163. Uppsala BIO
164. Vancouver Prostate Centre
165. Veolia Environnement
166. Veracyte
167. Veridex
168. Viatar CTC Solutions
169. Virginia Commonwealth University
170. Vitatex
171. VolitionRx ?

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

  • $ 5000
  • Industry report
  • August 2016
  • by Future Market Insight Global & Consulting Pvt Ltd

Report Synopsis This report by Future Market Insights (FMI) examines the ‘Liquid Biopsy Market’ for the period 2016–2026. The primary objective of the report is to offer updates and information ...

Breast Biopsy Device Market Analysis By Test Type, By Product, By Guidance Type, By Region And Segment Forecasts To 2024

Breast Biopsy Device Market Analysis By Test Type, By Product, By Guidance Type, By Region And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The breast biopsy device market is expected to reach USD 911.2 million by 2024, according to a new report by Grand View Research, Inc. The Breast biopsy device market is projected to grow at a productive ...

Liquid Biopsy Market Size & Forecast By Application, By Sample Type, By Biomarker Type, By Technology and Trend Analysis from 2013 to 2030

Liquid Biopsy Market Size & Forecast By Application, By Sample Type, By Biomarker Type, By Technology and Trend Analysis from 2013 to 2030

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

Global liquid biopsies market is anticipated to reach 5,958.3 million by 2030, according to a new report by Grand View Research, Inc. As these less invasive biopsies are able to address a number of significant ...


Download Unlimited Documents from Trusted Public Sources

Biopsy Industry in the US

  • October 2016
    7 pages
  • Biopsy  

    Magnetic Resona...  

    Cancer  

  • United States  

View report >

Biopsy Industry in the US

  • August 2016
    2 pages
  • Biopsy  

  • United States  

    North America  

View report >

Biopsy Industry in the US

  • August 2016
    4 pages
  • Biopsy  

  • United States  

View report >

Related Market Segments :

Biopsy
Cancer
Biomarker

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.